Trials / Completed
CompletedNCT03004833
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Infusion of Nivolumab |
| DRUG | Adriamycin | Infusion of Adriamycin |
| DRUG | Vinblastine | Infusion of Vinblastine |
| DRUG | Dacarbazine | Infusion of Dacarbazine |
Timeline
- Start date
- 2017-02-21
- Primary completion
- 2022-08-22
- Completion
- 2022-08-22
- First posted
- 2016-12-29
- Last updated
- 2025-04-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03004833. Inclusion in this directory is not an endorsement.